EGFR and non-small cell lung carcinoma: Compared with reversible first-generation TKIs, irreversible second-generation TKIs showed improved progression-free survival (PFS), and in the case of dacomitinib, improved overall survival (OS) at the cost of increased toxicity for EGFR-mutant advanced NSCLC (Park et al., 2016; Mok et al., 2018).